Johnson & Johnson and Smith & Nephew end merger talks over leadership dispute

Johnson & Johnson’s orthopaedics unit and Smith & Nephew halted merger negotiations after they could not agree on who would run the combined company. The parties had aligned on financial terms, valuing the orthopaedics business at up to $22 billion and giving J&J shareholders a 50.1% stake in the proposed entity. J&J had proposed Namal Nawana as CEO, while Smith & Nephew insisted on retaining its own chief, Deepak Nath. The collapse revives J&J’s plan to spin off the orthopaedics unit, with a pro‑forma expected in December 2024 and the separation targeted for mid‑2027.

The news sent Johnson & Johnson shares down 1.42% on the day of the announcement. The spin‑off plan, now the likely path, could affect the valuation of J&J’s remaining businesses and the future price of the DePuy Synthes stock that will be distributed to shareholders.

  • 1The deal would have valued Johnson & Johnson’s orthopaedics unit at up to $22 billion, nearly twice Smith & Nephew’s market value.
  • 2Johnson & Johnson shareholders would have owned 50.1% of the combined company.
  • 3The leadership dispute centered on J&J’s pick, Namal Nawana, versus Smith & Nephew’s CEO Deepak Nath.
  • 4Johnson & Johnson’s shares closed down 1.42% at $263.81 following the collapse announcement.
  • 5J&J is now leaning toward a spin‑off of the orthopaedics unit, with the separation expected in mid‑2027 and a pro‑forma to be released on December 8.

Sources